The company has developed a unique drug-device combination product called Staccato alprazolam, which is designed to quickly and effectively stop active and acute epileptic seizures. This handheld inhaler utilizes FDA-approved delivery technology to administer alprazolam, an FDA-approved benzodiazepine, in a single breath. In a Phase 2a proof of concept study, Staccato alprazolam demonstrated a reduction in seizures in a photosensitivity model. With plans to leverage a 505(b)(2) regulatory pathway, Engage Therapeutics aims to advance this product into advanced clinical settings. This innovative solution provides individuals with epilepsy and their caregivers with a potential way to halt ongoing seizures, offering a much-needed rescue therapy option.